Orthox
Developes tissue regenerative implants which enable patients to return to a fully active, pain-free lifestyle.
| GBP | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Orthox is a pioneering company in the life sciences sector, focusing on innovative solutions for knee injuries. The company operates in the medical technology market, specifically targeting patients with cartilage and meniscus injuries in the knee. These injuries can lead to severe disability and often result in the need for total knee replacement, a costly and invasive procedure. Orthox aims to provide a less invasive alternative through its lead product, Cartilage, a natural implant designed to restore knee function and promote the body's own healing processes.
Orthox primarily serves patients who are at risk of or are already experiencing knee joint deterioration. This includes both young and older individuals who suffer from knee injuries that could lead to osteoarthritis. The company's products are particularly beneficial for those who want to avoid the limitations and risks associated with total knee replacement surgery.
The business model of Orthox revolves around the development, clinical testing, and eventual commercialization of its knee cartilage repair products. The company has secured significant funding from various prestigious sources, including the EU Horizon 2020 programme and the NIHR i4i programme. These funds are being used to advance the clinical strategy and bring their innovative solutions to market.
Orthox generates revenue through the sale of its medical implants once they pass clinical trials and receive regulatory approval. The company also benefits from grants and awards that support its research and development activities. By focusing on a niche but growing market, Orthox aims to address a critical medical need and reduce the number of total knee replacement surgeries performed annually.
In summary, Orthox is a forward-thinking company dedicated to improving knee health through natural, resilient implants that restore function and promote healing. Their innovative approach and strong financial backing position them well in the competitive medical technology market.
Keywords: Orthox, knee injuries, cartilage repair, medical implants, life sciences, osteoarthritis, clinical trials, EU Horizon 2020, NIHR i4i, healthcare innovation.